搜尋
Xencor Inc
XNCR添加自選
15.000USD
-0.380-2.47%
收盤 07/02, 13:00（美東）報價延遲15分鐘
1.08B總市值
虧損本益比TTM
關鍵數據
15.390今開
15.720最高
919.42K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.28%換手率
15.380昨收
14.690最低
10.12M成交額
虧損本益比靜
1.70市淨率
0.00%股息率 TTM
-21.01%ROA
18.69052週最高
1.39量比
-232.62M淨利潤
71.87M總股本
-2.2942每股盈餘TTM
0.92Beta
-29.84%ROE
6.92052週最低
6.70%振幅
100.00%毛利率
1.08B總市值
9.42回報/風險
3.68%風險率
TradingKey Xencor Inc股票評分
單位: USD 更新時間: 2026-07-01操作建議
Xencor Inc當前公司基本面數據相對穩定，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名73/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為29.82。中期看，股價處於上升通道。近一個月，市場表現很強，技術面評分較高，但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Xencor Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Xencor Inc亮點
亮點風險
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
估值合理
公司最新PE估值-6.70，處於3年歷史合理位
分析師目標
基於
14
分析師
買入
評級
29.818
目標均價
+85.21%
漲幅空間
Xencor Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Xencor Inc簡介
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
公司代碼XNCR
公司Xencor Inc
CEODahiyat (Bassil I)
網址https://xencor.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52842.500
+588.200 (+1.13%)
29311.400
-487.900 (-1.64%)
7471.500
-4.000 (-0.05%)
14803.000
-552.000 (-3.60%)
68148.000
-1337.000 (-1.92%)
6352.800
+77.400 (+1.23%)
68.344
+0.376 (+0.55%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4121.910
+91.140 (+2.26%)
常見問題
Xencor Inc(XNCR)的當前股價是多少？
Xencor Inc(XNCR)的當前股價是 15.38。
Xencor Inc 的股票代碼是什麼？
Xencor Inc的股票代碼是XNCR。
Xencor Inc股票的52週最高點是多少？
Xencor Inc股票的52週最高點是18.69。
Xencor Inc股票的52週最低點是多少？
Xencor Inc股票的52週最低點是6.92。
Xencor Inc的市值是多少？
Xencor Inc的市值是1.14B。
現在Xencor Inc(XNCR)的股票是買入、持有還是賣出？
根據分析師評級，Xencor Inc(XNCR)的總體評級為買入，目標價格為29.82。
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是多少
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是-1.24。